WallStSmart
VTAK

Catheter Precision Inc.

AMEX: VTAK · HEALTHCARE · MEDICAL DEVICES

$0.86
+0.98% today

Updated 2026-06-05

Market cap
$2.88M
P/E ratio
P/S ratio
2.60x
EPS (TTM)
$-10.48
Dividend yield
52W range
$1 – $7
Volume
0.1M

Catheter Precision Inc. (VTAK) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2016201720182019202020212022202320242025
Operating cash flow$-1.89M$-5.52M$-18.51M$-33.17M$-28.30M$-27.63M$-22.57M$-20.62M$-9.27M$-8.30M
Capital expenditures$210000.00$547000.00$582000.00$268000.00$67000.00$265000.00$17000.00$76000.00$67000.00$17000.00
Depreciation
Stock-based comp$2.30M$12.71M$14.73M$23.54M$4.08M$2.24M$447000.00$1.22M$54000.00$338000.00
Free cash flow$-2.10M$-6.07M$-19.09M$-33.44M$-28.37M$-27.89M$-22.59M$-20.70M$-9.34M$-8.31M
Investing cash flow
Financing cash flow
Dividends paid$907161.00$5.16M
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Catheter Precision Inc.'s revenue?

Catheter Precision Inc.'s trailing twelve-month revenue is $1.11M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is VTAK?

In its most recent fiscal year, VTAK ran a gross margin of 92.31%, an operating margin of -1,487.30%, and a net margin of -2,098.05%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does VTAK generate?

VTAK produced $-8.31M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is VTAK's balance sheet healthy?

VTAK holds $88000.00 in cash and equivalents against $3.08M in long-term debt, on $7.05M of shareholder equity. That debt is best read against the cash flow the business throws off each year.